Company intelligence / Profile preview
Akari Therapeutics
New York, New York, United Statesakaritx.com ↗
- Ownership
- Public · AKTX
- Development stage
- Other
01
Overview
Developing bispecific complement/LTB4 inhibitors and novel ADCs targeting cancer through RNA splicing disruption. Lead ADC candidate AKTX-101 shows preclinical promise against multiple cancers.
- Therapeutic areas
- OphthalmologyHematologyOncology
- Modalities
- Antibody-drug conjugates (ADCs)Recombinant proteinsbispecific inhibitors
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
Wacker Biotech GmbH (manufacturing partner)
04
Financials
- Market cap
- $17.8M
- Total revenue
- $0
- Enterprise value
- $10.8M
Beyond the preview
Go deeper on Akari Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akari Therapeutics.